1,5-Diaryl-pyrazoles and their use as cannabinoid receptor neutral antagonists

Iain Robert Greig (Inventor), Ruth Alexandra Ross (Inventor)

Research output: Patent


The present invention pertains to cannabinoid (CB) receptor and cannabinoid-like receptor neutral antagonists, and especially CB1 neutral antagonists of Formula (I). The present invention also pertains to these compounds for use in the treatment of diseases and disorders that are ameliorated by treatment with a neutral antagonist of the cannabinoid type 1 (CB1) receptor or a non-CB1/non-CB2 cannabinoid-like receptor, for example: an eating disorder; obesity; cardiovascular disease; a disease or disorder characterised by an addiction component; addiction; withdrawal; smoking addiction; smoking withdrawal; drug addiction; drug withdrawal; smoking cessation therapy; a bone disease or disorder; osteoporosis, Paget' s disease of bone; bone related cancer; breast cancer; breast cancer metastases; breast cancer which has metastasised to bone; cancer associated with activation or inactivation of a non-CB1/non-CB2 cannabinoid-like receptor,
Original languageEnglish
Patent numberWO2010020762
Publication statusPublished - 25 Feb 2010


Dive into the research topics of '1,5-Diaryl-pyrazoles and their use as cannabinoid receptor neutral antagonists'. Together they form a unique fingerprint.

Cite this